ロード中...
Antibody Drug Conjugates: Preclinical Considerations
The development path for antibody drug conjugates (ADCs) is more complex and challenging than for unmodified antibodies. While many of the preclinical considerations for both unmodified and antibody drug conjugates are shared, special considerations must be taken into account when developing an ADC....
保存先:
| 出版年: | AAPS J |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4406963/ https://ncbi.nlm.nih.gov/pubmed/25724883 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-015-9738-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|